Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) announced it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026, at 11:00 AM ET. The session will feature Max Jacob Liebo, MD, from Loyola University Medical Center, alongside Nick Ioannou, MD, MHA, Vice President of Medical Affairs at iMDx, and Josh Riggs, Chief Executive Officer. The discussion will focus on the company’s GraftAssure platform, which utilizes digital PCR technology to provide donor-derived cell-free DNA (dd-cfDNA) results for monitoring transplanted organ health. This event highlights iMDx’s strategy to transition organ rejection testing from centralized send-out services to in-house laboratory capabilities.

The primary objective of the presentation is to outline how a kitted version of the test, known as GraftAssureDx, could be utilized for in-house heart transplant rejection monitoring. Dr. Liebo is expected to address the implications of this shift for both the healthcare industry and patient outcomes. Currently, GraftAssure is under review by the U.S. Food and Drug Administration (FDA) for commercialization in a kitted form, intended for laboratory use in testing patients for kidney transplant rejection. A live question-and-answer session will follow the main presentation.

Strategic Shifts in Transplant Monitoring

iMDx identifies three potential paradigm shifts in the landscape of transplanted organ health monitoring, driven by the GraftAssure technology:

The company emphasizes that dd-cfDNA is an established biomarker for assessing transplanted organ health through a simple blood draw. By measuring both dd-cfDNA percentage and absolute concentrations as copies per milliliter of plasma, GraftAssure aims to support more comprehensive clinical decision-making.

Product Portfolio Overview

iMDx’s transplant diagnostics portfolio under the GraftAssure brand includes several distinct offerings tailored to different stages of clinical and research application:

• GraftAssureCore: A laboratory-developed test (LDT) currently reimbursed by CMS and performed at iMDx’s CLIA-certified laboratory in Franklin, Tennessee.
• GraftAssureIQ: A research-use-only (RUO) kit labeled for non-clinical applications.
• GraftAssureDx: An in vitro diagnostic (IVD) kit currently undergoing FDA review for use in clinical decision-making.

Executive Profiles

Max Jacob Liebo, MD, specializes in cardiovascular disease and internal medicine at Ronald McDonald Children’s Hospital of Loyola University Medical Center. His background includes fellowships at Cleveland Clinic Hospital and Scripps Green Hospital.

Nick Ioannou, MD, MHA, brings over three decades of experience in medical affairs, having previously held senior roles at Guardant Health, Natera, and Fresenius. Josh Riggs, who joined iMDx in August 2020, serves as Interim CEO after previously founding Intelliger Consulting.

Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) reported second-quarter 2026 adjusted earnings per share (EPS) of $(0.23), beating the analyst consensus estimate of $(0.24) by 4.17 percent. While top-line revenue fell short of expectations at $239,000, missing the $437,500 estimate by 45.37 percent, the company highlighted significant regulatory progress, noting that the U.S. Food and Drug Administration completed the current phase of its substantive review of GraftAssureDx in late July. This milestone, combined with favorable Medicare reimbursement policies issued in July, positions the company to advance toward marketing authorization for its flagship transplant monitoring test.

The financial results reflect a strategic shift from pre-commercial development toward launch preparation. The company recorded a GAAP net loss of $11.3 million, or $(0.31) per share, driven largely by a non-cash loss of $2.3 million from a change in the fair value of contingent consideration. Operating expenses totaled $11.6 million, including $661,000 in stock-based compensation and $641,000 in depreciation and amortization. Excluding these non-cash items, non-GAAP operating expenses decreased 13 percent sequentially from the first quarter, reflecting the winding down of costs associated with the FDA submission.

Financial Performance Overview

The divergence between the EPS beat and the revenue miss underscores the company's pre-revenue status regarding its core commercial product. The following table details Insight Molecular's key financial metrics for the quarter:

Revenue was primarily derived from laboratory services performed at its clinical laboratory in Tennessee, with an additional $21,000 from research-use-only kit sales. Management emphasized that material revenue from kitted products is not expected until after regulatory authorization is achieved. Gross profit stood at $157,000, representing a 65.7 percent gross margin.

Regulatory and Commercial Progress

The FDA’s timely completion of the substantive review phase marks a critical step in the authorization process for GraftAssureDx, which was submitted in late March. The agency has requested additional information, a standard procedure, leaving the company with a clear set of remaining items. Concurrently, MolDX issued a favorable Medicare local coverage decision expanding reimbursement for dd-cfDNA testing, doubling testing rates in the second and third years post-kidney transplant to four tests per year. This policy significantly increases the surveillance testing opportunity for GraftAssureDx.

Clinical evidence continues to bolster the case for adoption. A study published in Kidney International demonstrated that dd-cfDNA levels declined early during daratumumab treatment for antibody-mediated rejection, reinforcing the biomarker's role in guiding therapy. Additionally, data in Clinical Chemistry showed 99.2 percent agreement between GraftAssure’s digital PCR technology and a leading NGS-based competitor, with superior analytical sensitivity. These findings support the company’s strategy of shifting testing from send-out services to in-house laboratory settings.

What the Numbers Show

The financial data reveals a deliberate cost discipline strategy as the company transitions from R&D-heavy submission work to commercial preparation. Research and development expenses decreased 9 percent sequentially to $4.5 million, while sales and marketing expenses fell to $1.9 million. However, the widening GAAP net loss, partially driven by the $2.3 million contingent consideration adjustment, highlights the volatility inherent in acquisition-related accounting. With cash and cash equivalents totaling $18.7 million at the end of the quarter and outgoing free cash flow of approximately $10 million, the company maintains sufficient liquidity to fund operations through the anticipated commercial launch phase. The sequential decline in operating expenses suggests that the peak spending period associated with regulatory submission has passed.